This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). 

Patients in Arm 1 will receive Nivolumab intravenously every 2 weeks. Patients in Arm 2 will receive a Motolimod as IT injection weekly. Arm 3 Nivolumab intravenously and Motolimod as IT injection weekly. Arm 4 will receive Nivolumab intravenously and Motolimod via SC injection. 

(VTX-2337-HN-001, IRB 2020-0736)

IRB 2020-0078
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
IRB 2020-0625
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Research Recruitment just got an Upgrade!!

The new High Enroll mobile app is now available to UC Cancer Center members and outside affiliates. The app has a new look and exciting new features to support the recruitment of patients into our research studies.

The UC Cancer Center continues to partner with High Enroll, LLC, to make recruitment easier and more enjoyable. We hope you will find the updated mobile application even more helpful. The new app will continue to provide all the information you need at your fingertips for discussing research with a patient. Some of the new features include: more content fields for each study; updates on studies via push notifications; the ability to save a study as a “favorite”; the ability to share a specific study with an interested colleague; and the ability to provide scheduled coordinator contact coverage 24/7.

The upgraded version of the mobile app is available for anyone at UC or beyond. It takes only seconds to get the new app. You can scan the QR code above, download it directly from the App Store, or wait for us to provide you a download link from the previous High Enroll app.

If you have any questions, please research out to your UC Cancer Center research team or High Enroll at 513.993.0330.

WOSU: Breast cancer screening and transgender patients

Research shows that LGBTQ+ people tend to delay regular health screenings, and therefore, get later stage cancer cancer diagnoses that often lead to worse outcomes. UC expert, Annie Brown discusses new guidelines for this population. 
Click Here to Visit the UC Newsroom
National Cancer Institute: Supporting Cancer Survivors 

Friday, May 28, 2021  | 12:00-1:00pm
Virtual only, no registration required.

Access virtual event at: 

For more information or questions, email, or call 513-558-2030.

View Flyer as PDF
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Center Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA